Epizyme, Inc.

NasdaqGS:EPZM 株式レポート

時価総額：US$247.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Epizyme マネジメント

マネジメント 基準チェック /24

主要情報

Grant Bogle

最高経営責任者

US$3.0m

報酬総額

CEO給与比率9.9%
CEO在任期間less than a year
CEOの所有権n/a
経営陣の平均在職期間2.3yrs
取締役会の平均在任期間10.2yrs

経営陣の近況

Recent updates

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

May 16
Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

Epizyme: Taking Advantage Of Recent Sell-Off

Nov 25

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Sep 14
Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Aug 10
Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Jun 22

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jun 08
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Jun 02

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Feb 25
Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jan 16
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Dec 24

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Dec 12
Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Epizyme Q3 2020 Earnings Preview

Nov 05

CEO報酬分析

Epizyme の収益と比較して、Grant Bogle の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2022n/an/a

-US$208m

Mar 31 2022n/an/a

-US$236m

Dec 31 2021US$3mUS$299k

-US$251m

Sep 30 2021n/an/a

-US$267m

Jun 30 2021n/an/a

-US$257m

Mar 31 2021n/an/a

-US$251m

Dec 31 2020US$196kn/a

-US$232m

Sep 30 2020n/an/a

-US$222m

Jun 30 2020n/an/a

-US$202m

Mar 31 2020n/an/a

-US$192m

Dec 31 2019US$309kn/a

-US$173m

報酬と市場: Grantの 総報酬 ($USD 3.01M ) は、 US市場 ($USD 1.46M ) の同規模の企業の平均を上回っています。

報酬と収益: Grantの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Grant Bogle (64 yo)

less than a year

在職期間

US$3,011,807

報酬

Mr. Grant C. Bogle has been Chief Executive Officer, President and Director at Epizyme, Inc. since August 9, 2021 and serves as Principal Financial Officer since November 1, 2021 and served as its Independ...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Grant Bogle
Presidentless than a yearUS$3.01mデータなし
Jeffery Kutok
Chief Scientific Officer2.3yrsUS$2.86m0.0080%
$ 19.9k
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno dataデータなしデータなし
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno dataデータなしデータなし
Jerald Korn
Chief Operating Officerless than a yearデータなしデータなし
Joseph Beaulieu
Senior VP4.1yrsデータなし0.0058%
$ 14.3k
Craig West
Vice President of Investor Relationsno dataデータなしデータなし
John Weidenbruch
Senior VPno dataデータなしデータなし
Tanja Weber
Chief Business Officer3.6yrsデータなしデータなし
Mark De Rosch
Chief Regulatory Officer2.8yrsデータなしデータなし
Rebecca Mehrwerth
Senior VP & Head of Commercialless than a yearデータなしデータなし
Christoph Diefenbach
Laboratory Manager of Research & Developmentno dataデータなしデータなし

2.3yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: EPZMの経営陣は 経験豊富 であると考えられます ( 2.3年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Grant Bogle
President2.9yrsUS$3.01mデータなし
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno dataデータなしデータなし
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno dataデータなしデータなし
George Daley
Member of the Scientific Advisory Boardno dataデータなしデータなし
David Mott
Independent Chairman12.7yrsUS$370.00k0.19%
$ 474.0k
Carl Goldfischer
Independent Director12.9yrsUS$350.00k0.0030%
$ 7.4k
Christopher Walsh
Member of the Scientific Advisory Boardno dataデータなしデータなし
Kenneth Bate
Independent Director7.7yrsUS$330.94k0%
$ 0
Bruce Chabner
Member of the Scientific Advisory Boardno dataデータなしデータなし
Ronald Evans
Member of the Scientific Advisory Boardno dataデータなしデータなし
Joel Huff
Member of the Scientific Advisory Boardno dataデータなしデータなし
Steven Henikoff
Member of the Scientific Advisory Boardno dataデータなしデータなし

10.2yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: EPZMの 取締役会 は経験豊富で 経験豊富 です ( 10.2年の平均在任期間)。